Page 87 - Read Online

Song et al. Hepatoma Res 2020;6:27 I http://dx.doi.org/10.20517/2394-5079.2020.05 Page 15 of 15

disease severity and intestinal microbiota in adults with nonalcoholic fatty liver disease. Int J Mol Med 2018;42:2229-37.
132. Zhang F, Jiang WW, Li X, Qiu XY, Wu Z, et al. Role of intrahepatic B cells in non-alcoholic fatty liver disease by secreting pro-
inflammatory cytokines and regulating intrahepatic T cells. J Dig Dis 2016;17:464-74.
133. Bruzzi S, Sutti S, Giudici G, Burlone ME, Ramavath NN, et al. B2-Lymphocyte responses to oxidative stress-derived antigens
contribute to the evolution of nonalcoholic fatty liver disease (NAFLD). Free Radic Biol Med 2018;124:249-59.
134. Zhang JC, Chen WD, Alvarez JB, Jia K, Shi L, et al. Cancer immune checkpoint blockade therapy and its associated autoimmune
cardiotoxicity. Acta Pharmacol Sin 2018;39:1693-8.
135. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, et al. Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.
136. Yau T, Hsu C, Kim TY, Choo SP, Kang YK, et al. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian
cohort analysis. J Hepatol 2019;71:543-52.
137. Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, et al. Pembrolizumab as second-line therapy in patients with advanced
hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol 2020;38:193-202.
138. Pishvaian MJ, Lee MS, Ryoo BY, Stein S, Lee KH, et al. Updated safety and clinical activity results from a phase Ib study of
atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). Ann Oncol 2018;29:viii718-9.
139. Roche’s Tecentriq in combination with Avastin increased overall survival and progression-free survival in people with unresectable
hepatocellular carcinoma. Available from: https://www.roche.com/media/releases/med-cor-2019-10-21.htm [Last accessed on 14 Apr
2020]
140. Faivre S, Rimassa L, Finn RS. Molecular therapies for HCC: looking outside the box. J Hepatol 2020;72:342-52.
141. Tang ZS, Hao YH, Zhang EJ, Xu CL, Zhou Y, et al. CD28 family of receptors on T cells in chronic HBV infection: Expression
characteristics, clinical significance and correlations with PD-1 blockade. Mol Med Rep 2016;14:1107-16.
142. Yin Y, Wu C, Song J, Wang J, Zhang E, et al. DNA immunization with fusion of CTLA-4 to hepatitis B virus (HBV) core protein
enhanced Th2 type responses and cleared HBV with an accelerated kinetic. PLoS One 2011;6:e22524.
143. Schurich A, Khanna P, Lopes AR, Han KJ, Peppa D, et al. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on
apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 2011;53:1494-503.
144. Wang X, He Q, Shen H, Lu XJ, Sun B. Genetic and phenotypic difference in CD8(+) T cell exhaustion between chronic hepatitis B
infection and hepatocellular carcinoma. J Med Genet 2019;56:18-21.
145. Sangro B, Gomez-Martin C, de la Mata M, Inarrairaegui M, Garralda E, et al. A clinical trial of CTLA-4 blockade with tremelimumab
in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013;59:81-8.
146. Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, et al. Tremelimumab in combination with ablation in
patients with advanced hepatocellular carcinoma. J Hepatol 2017;66:545-51.
147. Kelley RK, Abou-Alfa GK, Bendel JC, Kim TY, Borad MJ, et al. Phase I/II study of durvalumab and tremelimumab in patients with
unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses. J Clin Oncol 2017;35.
148. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
New Engl J Med 2013;368:1509-18.
149. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia.
New Engl J Med 2014;371:1507-17.
150. Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, et al. T cells genetically modified to express an anti-B-cell maturation antigen
chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol 2018;36:2267.
151. Gao H, Li K, Tu H, Pan X, Jiang H, et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular
carcinoma. Clin Cancer Res 2014;20:6418-28.
152. Wu X, Luo H, Shi B, Di S, Sun R, et al. Combined antitumor effects of sorafenib and GPC3-CAR T cells in mouse models of
hepatocellular carcinoma. Mol Ther 2019;27:1483-94.
153. Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies.
Cancer J 2014;20:119-22.
154. Oelsner S, Waldmann A, Billmeier A, Roder J, Lindner A, et al. Genetically engineered CAR NK cells display selective cytotoxicity
against FLT3-positive B-ALL and inhibit in vivo leukemia growth. Int J Cancer 2019;145:1935-45.
155. Chu J, Deng Y, Benson DM, He S, Hughes T, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells
enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 2014;28:917-27.
156. Xiao L, Cen D, Gan H, Sun Y, Huang N, et al. Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal
cancer patients. Mol Ther 2019;27:1114-25.
157. Zhang C, Burger MC, Jennewein L, Genssler S, Schonfeld K, et al. ErbB2/HER2-specific NK cells for targeted therapy of
glioblastoma. J Natl Cancer Inst 2016;108.